Vericel Corporation filings document regulatory disclosures for a commercial-stage biopharmaceutical company focused on cell therapies and specialty biologics for sports medicine and severe burn care. Recent Form 8-K reports furnish operating and financial results, preliminary estimates, guidance updates and business highlights tied to MACI, Epicel and NexoBrid.
Proxy and annual meeting filings describe board elections, advisory votes on executive compensation, auditor ratification and other shareholder voting matters. The filing record also identifies Vericel as a Michigan corporation and provides formal disclosure around governance, financial reporting events and product-related commercial performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.07%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.07%
Tags
FAQ
How many Vericel (VCEL) SEC filings are available on StockTitan?
StockTitan tracks 63 SEC filings for Vericel (VCEL), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Vericel (VCEL)?
The most recent SEC filing for Vericel (VCEL) was filed on August 6, 2025.